Pfizer stock (NYSE: PFE) is favored over AbbVie due to its better valuation. With a lower multiple and strong revenue growth potential, Pfizer is expected to outperform AbbVie in the coming years.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing